ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Zynerba Pharmaceuticals, Inc. (ZYNE) stock surged +2.36%, trading at $1.30 on NASDAQ, up from the previous close of $1.27. The stock opened at $1.26, fluctuating between $1.26 and $1.34 in the recent session.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
Employees | 25 |
Beta | 1.19 |
Sales or Revenue | $0.00 |
5Y Sales Change% | -1% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |